Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297400 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
A Phase 2 study of Burns, sponsored by Skingenix.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT01297400: Recruiting Phase 2 study of Burns, sponsored by Skingenix.
NCT01297400 is a Phase 2 study of Burns that is actively recruiting participants, run by Skingenix. The registered enrollment target is 60 participants, below the 82-participant average among 36 other Burns trials with a reported enrollment target (27% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01297400, a Phase 2 study of Burns, is actively recruiting participants, sponsored by Skingenix.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Primary Outcome
Time to healing (≥95% re-epithelialization) of the partial thickness target burn.
Conditions Studied
Interventions
- DRUG Investigational Drug, MW-III
- DRUG Silvadene® Cream 1% [Silver Sulfadiazine]
Study Locations (6)
Other
- Proactive CR Mexico SA de CV - Irapuato
- SMIQ S de R. L de CV - Querétaro City
Arizona
- Valleywise Health Medical Center - Phoenix
California
- University of CA Davis Medical Center - Sacramento
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Iowa
- University of Iowa Health Care - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT01297400 shows while recruiting
NCT01297400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 82-participant average among 36 other Burns trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Investigational Drug, MW-III is the first listed.
NCT01297400 lists 6 locations in 5 states (Other, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT01297400 about?
NCT01297400 is a clinical study titled "Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns". To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
What is the current status of trial NCT01297400?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-03-11. Estimated completion is 2026-12-31.
What conditions does trial NCT01297400 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT01297400?
The interventions under investigation include: Investigational Drug, MW-III (DRUG), Silvadene® Cream 1% [Silver Sulfadiazine] (DRUG).
Who is sponsoring clinical trial NCT01297400?
This trial is sponsored by Skingenix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01297400 being conducted?
This trial has 6 study locations across Arizona, California, District of Columbia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01297400's enrollment target sits among peer trials
60 13th of 36 higher than 23 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
4-Aminopyridine to Treat Skin Burns
RECRUITING · Phase 2
-
Cranial Electrotherapy Stimulation in Burned Patients
COMPLETED · Phase 2
-
VR for Burn Dressing Changes at Home
COMPLETED · Phase 2
-
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
COMPLETED · Phase 2
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- NCT02114450 · 60 participants · NA
Human-Machine System for the H2 Lower Limb Exoskeleton
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI